KOSDAQBiotech & Pharma084990

Helixmith

₩3,275▲ 0.77%2026-11-18 close
Market Cap
₩151B
Turnover
₩400M
Volume
140K
Shares out.
46.1M
PER
—
PBR
1.2×
EPS
-₩49
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

China approval, narrower losses, partnering next

China's approval of Engensis-based NL003 opened a royalty path for Helixmith, but reported revenue remains small and net losses have continued over the last four quarters.

  1. 1

    In late May 2026 China's NMPA approved NL003, based on Engensis, from partner Northland Biotech for critical limb ischemia, and Helixmith will receive a royalty on NL003 sales for seven years.

  2. 2

    Reported 2025 results show revenue of KRW 2.6 billion, an operating loss of KRW 9.9 billion and a net loss attributable to controlling shareholders of KRW 435 million. The operating loss has narrowed every year since 2022, while revenue fell from KRW 4.97 billion in 2024 to KRW 2.6 billion in 2025.

  3. 3

    Net income attributable to controlling shareholders turned positive at KRW 2.87 billion in the fourth quarter of 2025, but losses returned in each of the first three quarters of 2026.

  4. 4

    The U.S. DPN phase 3 re-run and global partnering for CLI are still at an early stage, and the 2026 annual report is the next checkpoint for the financial position and cash flow.

02

Business structure

Helixmith is a biotech company whose core asset is Engensis (VM202), a plasmid DNA-based gene therapy. Engensis was developed to induce angiogenesis and neural regeneration, targeting critical limb ischemia (CLI), diabetic peripheral neuropathy (DPN) and amyotrophic lateral sclerosis (ALS).

In the United States, the company completed a phase 2 trial in CLI, while its phase 3 DPN trials (3-2 and 3-2b) did not meet the primary endpoint. The first commercial path opened when Northland Biotech, the Chinese partner, obtained approval for NL003.

Helixmith will receive royalties on NL003 sales for seven years at a set percentage. The company also continues selectively with CAR-based cell and gene therapy platform technology, AAV and antibody pipelines, and runs a natural-product health food business.

After a management rights transfer and a third-party allotment rights offering in December 2023, Bio Solution became the largest shareholder, holding 18.23% as of a September 2026 report. Because reported revenue is small, the size and timing of royalties and other income largely determine the financial results.

Competition is framed against gene therapy developers in general, and global pharmaceutical companies are cited as potential counterparties beyond the Chinese partner.

In September 2026 the company joined a Ministry of Trade, Industry and Energy R&D project on AI-based manufacturing processes for cell and gene therapies.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩600M-₩2.7B−474.0%
2025Q4₩500M-₩2.4B−484.2%
2026Q1₩600M-₩2.2B−395.9%
2026Q2₩800M-₩2.2B−269.7%
2026Q3₩400M-₩2.7B−596.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2.8B-₩52.6B-₩43.5B−1878.1%−20.1%17.4%
2023₩4.2B-₩35.2B-₩64.1B−838.9%−41.6%47.9%
2024₩5B-₩18B-₩15.5B−361.0%−10.9%4.8%
2025₩2.6B-₩9.9B-₩400M−381.0%−0.3%1.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual results show a small revenue base alongside narrowing operating and net losses. Revenue was KRW 2.8 billion in 2022, KRW 4.2 billion in 2023 (up 50.1% year on year) and KRW 4.97 billion in 2024 (up 18.4%), before falling to KRW 2.6 billion in 2025 (down 47.8%).

Among 2022 to 2025, 2024 was the largest year for revenue and 2025 the smallest. The operating loss narrowed from KRW 52.6 billion in 2022 to KRW 35.2 billion in 2023, KRW 18 billion in 2024 and KRW 9.9 billion in 2025, and the operating margin moved from -1,878.1% to -381.0%.

The company attributed the narrowing to restructuring of staff and pipeline, and said selling, general and administrative expenses fell from KRW 37.3 billion in 2023 to KRW 20.8 billion in 2024 and KRW 10.8 billion in 2025 on an internal-settlement basis.

The net loss attributable to controlling shareholders widened in 2023 to KRW 64.1 billion even though the operating loss narrowed, which points to a large non-operating effect, though the detailed items should be checked in the 2023 annual report. It then fell to KRW 15.5 billion in 2024 and KRW 435 million in 2025.

For 2025, the company said higher non-operating income from gains on certain financial products was a major factor behind the smaller net loss, which was KRW 460 million including non-controlling interests.

Quarterly, the net loss attributable to controlling shareholders was KRW 1.02 billion in the third quarter of 2025, then a KRW 2.87 billion profit in the fourth quarter (a turn to profit), followed by losses of KRW 1.4 billion, KRW 2.06 billion and KRW 1.7 billion in the first three quarters of 2026.

Revenue peaked at KRW 810 million in the second quarter of 2026 and was KRW 448 million in the third quarter, down 20.6% year on year. The operating loss was KRW 2.67 billion in the third quarter of 2026, larger than in the prior quarter. Operating cash outflow narrowed from KRW 40.7 billion in 2022 to KRW 6.9 billion in 2025.

05

Industry analysis

The demand side of the story is critical limb ischemia treatment.

The company puts the global CLI treatment market at several trillion won and highlights that China has approved a non-viral, plasmid DNA-based gene therapy as a first case, which it uses to re-explain the technical value of the Engensis IP to global partners.

On the cycle, industry commentary says cell and gene therapy is moving toward a stage where manufacturing quality and process precision determine competitiveness. A September 2026 report put the global cell imaging market at about USD 520 million in 2024, projected to reach about USD 980 million by 2030.

Against peers, large listed biotech companies such as Celltrion, Samsung Biologics and Alteogen have production scale and commercial products, whereas Helixmith has a small revenue base and no self-commercialized product yet.

Its distinguishing feature among gene therapy developers is that a Chinese approval and a U.S. phase 3 re-run are running in parallel. The company also stresses that chemistry, manufacturing and controls (CMC) make up a large share of the U.S. biologics license application review documents.

06

Outlook

The company has outlined three near-term items. First, Northland, the Chinese partner, is pursuing reimbursement of NL003 on China's National Reimbursement Drug List.

The 2026 schedule was set as an application in June and July, expert review in July and August, price negotiation in August and September, and final results in October and November.

Price levels and the impact on the insurance fund were flagged as the key issues, and one estimate suggests negotiated prices per treatment course could fall to around CNY 32,000 to 38,000. Second, a numbness-related indication is being prepared for a marketing application after its phase 3 trial was completed.

Third, in October 2026 the company said the U.S. FDA cleared the drug substance and drug product of Engensis for clinical use, and that the product would enter the DPN phase 3 trial soon. The CLI phase 3 is expected to be pursued with partners rather than alone.

Partnering options cited include licensing out, regional joint ventures, joint clinical development and local investment. The company attended BIO USA in June 2026 as a venue to push these discussions.

In September 2026 it also joined a five-year government R&D project with a total budget of KRW 6.54 billion, of which about KRW 4.75 billion is government funding.

07

Valuation

PER
—
PBR
1.2×
ROE
-1.7%
EPS
-₩49
BPS
₩2,966
Dividend per share
₩0

Valuation is read more through pipeline events than through earnings multiples. Because the net loss attributable to controlling shareholders over the last four quarters totals KRW 2.29 billion, a price-to-earnings ratio cannot be calculated.

The price-to-book ratio sits slightly above 1 times, meaning the premium over net asset value is modest. Market capitalization is above the book value attributable to controlling shareholders.

Total liabilities are only KRW 1.67 billion against total equity of KRW 141.5 billion, so financial burden is small, but with no operating profit yet, the share price reflects expectations tied to Chinese royalties and Engensis clinical results to a degree. No shareholder return through dividends is currently paid.

Whether the current price-to-book level sits in the middle of its historical band needs further data. Compared with larger listed biotech peers, the gap in revenue scale and cash generation is wide, so simple multiple comparisons are limited.

The outcome of the China NRDL process, the start of the DPN phase 3 trial and whether a partnership deal is signed are the variables that would change how the multiples are read.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Chinese approval and royalty path

The NL003 approval in late May 2026 moved Engensis IP into a commercial stage. Helixmith will receive royalties on NL003 sales at a set percentage for seven years. The partner is pursuing reimbursement under China's 2026 national drug list negotiations, and success could enlarge royalty-based income.

Partial easing of U.S. development risk

In October 2026 the company said the FDA cleared the drug substance and drug product of Engensis for clinical use. It noted that CMC accounts for a large part of U.S. BLA review documents and said the clearance would help technology transfer. This provides a base for the DPN phase 3 re-run.

Lower cost base and lighter balance sheet

Selling, general and administrative expenses fell from KRW 37.3 billion in 2023 to KRW 10.8 billion in 2025 on an internal-settlement basis. The debt ratio dropped from 47.9% in 2023 to 1.2% in 2025. Operating cash outflow narrowed from -KRW 40.7 billion in 2022 to -KRW 6.9 billion in 2025. A February 2026 report said cash and cash equivalents had grown to about KRW 80 billion.

09

Bear factors

Earlier DPN phase 3 setback

Engensis's DPN phase 3 trials (3-2 and 3-2b) did not meet their primary endpoint. The company plans to run a DPN phase 3 again with the newly cleared product, but the earlier results remain on record. Securing funding and partners is a precondition for a U.S. re-run, which adds to the burden.

Small revenue base and continued losses

Revenue was KRW 2.6 billion in 2025 against an operating loss of KRW 9.9 billion. Losses attributable to controlling shareholders continued in each of the first three quarters of 2026, and the third-quarter operating loss of KRW 2.67 billion was larger than the prior quarter.

Third-quarter 2026 revenue fell 20.6% year on year, so a structure that offsets losses from core operations has yet to appear.

China pricing and partner dependence

Royalty income depends on NL003 sales and pricing in China. One estimate suggests negotiated prices per treatment course could fall to around CNY 32,000 to 38,000 under national insurance negotiations.

Markets in the United States and Europe depend on signed partnerships, so both development progress and the timing of monetization hinge on outside negotiations.

10

Risk factors

Clinical and regulatory risk

If the DPN phase 3 again misses its primary endpoint, the broader indication strategy would be affected. The CLI phase 3 is hard to start before a partner is secured. FDA clearance for clinical use does not equal marketing approval, so clinical results and regulatory decisions will determine final value. The timing of the trial start that the company described as soon has not been fixed.

Partnering and royalty uncertainty

NL003 royalties depend on the partner's sales and the outcome of pricing negotiations. If reimbursement is not achieved or prices fall sharply, royalty income would shrink. Delays in global licensing would push back the medium-term revenue path. Because reported revenue is small, individual contract terms weigh heavily on results.

Financial and shareholder concentration risk

Losses attributable to controlling shareholders continued in each of the first three quarters of 2026, and the four-quarter total is KRW 2.29 billion. The largest shareholder, Bio Solution, held 18.23% as of a September 2026 report, so ownership is concentrated. The pace of cash depletion and any further fundraising should be checked in the 2026 annual report.

11

What to watch next

  1. November 2026

    Whether the final China NRDL results are announced in November. Listing status and price level determine the scale of royalty income.

  2. After December 2026 (timing not fixed)

    Disclosure of DPN phase 3 patient enrollment and first dosing. The start date sets the baseline for the next development timeline.

  3. After December 2026 (timing not fixed)

    Whether a licensing, joint clinical development or joint venture agreement is signed. Contract terms would shape the medium-term revenue structure.

  4. Mid-February 2027 (expected)

    Preliminary 2026 annual results, based on last year's timing for internal-settlement results. Preliminary figures precede the audited annual report.

  5. By March 31, 2027

    Filing of the 2026 annual report. Full-year 2026 operating loss, net loss attributable to controlling shareholders and cash flow are confirmed, setting the base for the next reported results.

12

Overall view

Helixmith has secured a royalty path through the Chinese approval of Engensis, but reported results remain at a stage of small revenue and continued operating losses.

Both the operating loss and the net loss attributable to controlling shareholders have narrowed each year since 2022, and the debt ratio and operating cash outflow have also fallen sharply.

However, losses attributable to controlling shareholders continued for three straight quarters from the first quarter to the third quarter of 2026, and third-quarter 2026 revenue declined year on year. The U.S. DPN phase 3 has a record of missing its primary endpoint, so the outcome of the re-run matters.

The next checkpoints are the China NRDL result, the start of the DPN phase 3 and any global partnership agreement, and the 2026 annual report will confirm the full-year financial position.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.news.nate.com
  2. edaily.co.kr
  3. m.news.nate.com
  4. mt.co.kr
  5. job-post.co.kr
  6. hankyung.com
  7. thinkpool.com
  8. medicopharma.co.kr
  9. thebionews.net
  10. mt.co.kr
  11. edaily.co.kr
  12. edaily.co.kr
  13. edaily.co.kr
  14. hankyung.com
  15. hankyung.com
  16. biotimes.co.kr
  17. edaily.co.kr
  18. pharmnews.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis